SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether RxSight, Inc. (NASDAQ: RXST), or any of its executive officers, violated federal securities laws by making false or misleading statements or failing to disclose material information to investors. What if I purchased RXST securities?If you purchased RxSight securities and suffered losses on your investment, you may be eligible to participate in our investigation. To join, please click here: ...

ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Preliminary Second Quarter 2025 Results Preliminary second quarter 2025 revenue is ...

最近，一个在日本福冈开业的新商场抢足风头。这个看似平平无奇的新商场，实则大有来头。它不仅引进了全日本最大规模的CHANEL旗舰店，且一半 品牌首次进军九州。 它就是位于九州第一繁华街区天神区、由西日本铁路打造的福冈新地标——One Fukuoka Bldg.。 作为"天神BIG BANG"街区大型改造计划的核心部分，该项目是由原福冈大楼、天神CORE和天神ビブレ整合重建改造而成的高层商业综合体。项目占地 面积8600㎡，建筑面积14.7万㎡，地上19层，地下4层，与地铁天神站10号出口相连，共引进超120个品牌。 项目开业前几天，商场外大排长队，商场里挤满了人。据媒体报道，该项目开业以来，日均客流达8万+人次。不少消费者认为"商场艺术氛围浓厚，每个 细节都看出了用心"，甚至有消费者表示"这种牌子特别、质感满分的逛街体验，我愿意N刷"。 图片来源：ins@tenjin_bb_log 图片来源：ins@mapfan01 01. 深挖艺术打造"小众但高级"商场 每个细节都是值得细品的用心 虽然是旧改项目，但One Fukuoka Bldg.并不只是简单的建筑翻新，它们希望从艺术和文化的角度深挖做内容，打造一个连接不 ...

自2023年起，东城区积极推动该项目落地，协调相关部门为审批流程提供专业指导，并开辟绿色通道保 障项目推进。同时，王府井地区管委会组织项目团队实地考察多个产业空间，最终选定王府中心作为项 目运营基地。 在签约现场，西甲联盟大中华区执行董事塞尔吉·托伦茨（Sergi Torrents）表示："在今天这个时代，球 迷沟通不应再是单向的，我们希望为球迷社群提供可以自主发起互动和项目的工具。" 据了解，该平台的核心是一个由Web3技术驱动的球迷社群生态系统，以球迷主导的"社团"结构为基 础，覆盖西甲旗下42家俱乐部的球迷，每个社团将围绕不同兴趣主题（如比赛、球员、明星以及内容类 型）建立。 LALIGA CLUB球迷社区项目具备多项开创性的功能，代表着中国球迷文化发展的新阶段。它通过将线 上互动与线下活动相结合，包括球迷活动、快闪、主题展示以及线下社区空间，实现真正的沉浸式体 验。 此外，平台引入了"边玩边赚""边逛边赚"的激励机制，鼓励球迷通过游戏、参与互动、内容创作和社区 建设获得奖励。平台还将设有去中心化市场，球迷可以在各个社团之间以及社团内部自由交易藏品、体 验与服务。同时，平台还引入了社区治理机制，为球迷提 ...

Summary of RxSight (RXST) Conference Call Company Overview - **Company**: RxSight (RXST) - **Event**: 2025 Conference on May 27, 2025 Key Industry Insights - **LAL Volumes**: April showed improvement over March, with late April trends indicating stabilization in macroeconomic conditions, which positively impacted procedural volumes [2][4][6] - **Premium IOL Market**: The premium intraocular lens (IOL) market in the U.S. has been largely flat over the years, with growth primarily driven by LAL, which accounts for 40-45% of its patient base coming from monofocal IOL patients [7][8] - **Market Recovery**: The company anticipates that the macroeconomic headwinds affecting premium IOLs are likely temporary, with expectations of improvement in the second half of the year as equity markets recover [12][18] Financial Performance and Guidance - **Utilization Trends**: The company noted that utilization has been impacted by macroeconomic factors and competition, but they are implementing new programs to enhance same-store sales and utilization [20][21] - **Sales Guidance for 2025**: The company expects LDD (Laser Delivery Device) sales to increase year-over-year, with the second half of 2025 projected to be stronger than the first half, contingent on macroeconomic stability [45][48] Competitive Landscape - **Competition from Alcon**: The introduction of PanOptix Pro by Alcon has created competition in the presbyopia-correcting IOL space, but the company believes significant clinical differences between products are unlikely [15][16] - **Market Share Dynamics**: RxSight has been gaining market share, with estimates suggesting they could reach 11-12% market share, while the overall market has been flat to down [36][37] Operational Strategies - **Utilization Programs**: The company is focusing on leveraging best practices from high-volume centers to improve utilization across their installed base, which is seen as a significant growth lever [21][24] - **Surgeon Training**: There is an ongoing effort to enhance the training of newer surgeon cohorts, as the 2024 class has not yet reached the same utilization levels as previous classes [27][30] Additional Considerations - **Psychological and Political Factors**: The company acknowledges that psychological and political factors will play a role in market recovery and consumer confidence, which are critical for achieving higher sales guidance [12][48] - **Long-term Growth Drivers**: The trend towards quality of vision over quantity is expected to continue driving growth in the premium IOL market, particularly with the LAL [12][24] This summary encapsulates the key points discussed during the conference call, highlighting the company's outlook, market dynamics, and strategic initiatives.

迪拜五大区域（市中心、商业湾、朱美拉棕榈岛、迪拜山庄、阿尔富江）各具优势，热销项目亮点突 出。 根据城市发展规划、重点企业项目表现，以及第三方Property Finder搜索量等最终选取具有代表的五大区 域，并进行进一步分析研究。 0 1 迪拜市中心 稀缺资产和地标价值凸显 The United Arab Emirates 迪拜市中心拥有哈利法塔、迪拜购物中心、音乐喷泉三大IP，年均吸引2000万游客，并推动高端公寓需 求， 尤其是中东及俄罗斯高净值投资者。 与此同时因土地资源稀缺且供应有限，2024年交付的住宅仅占 市场4%左右的比重，这种稀缺性使其房价和租金具有天然抗跌性。 | 維度 | 现状特征 | 未来潜力 | | --- | --- | --- | | 人口 | 密度高,以高净值及国际人士为主 | 持续吸引高端人才流入,人口规模与多元化程度提升 | | 产业 | 金融机构集聚,商业贸易繁荣,高端酒店餐饮 | 巩固金融核心地位,拓展商业规模,文旅产业协同升级 | | | 发达,文化娱乐设施丰富 | | | 住宅 | 以高端公寓、别墅为主,配套完善,集中于地 | 开发更趋高端智能,稀缺性凸显,房产价值 ...

Summary of RxSight (RXST) Q1 2025 Conference Call Company Overview - **Company**: RxSight (RXST) - **Industry**: Medical Technology, specifically focusing on ophthalmology and cataract surgery Key Points Q1 2025 Financial Performance - Q1 revenue grew by **28% year-over-year**, but fell short of market expectations [3][17] - LAL (Light Adjustable Lens) sales were impacted by macroeconomic factors, while LDD (Light Adjustable Lens Delivery) sales exceeded expectations [3][11] Macroeconomic Impact - The demographic typically resistant to economic downturns (60+ age group) showed signs of deferring treatments due to equity market shocks and changes in administration [5][6] - Patients cited economic concerns as reasons for deferring or canceling surgeries, a trend not seen since COVID-19 [6][14] Market Dynamics - The premium IOL market has been flat to declining, with RxSight's growth primarily driven by LAL sales [9][10] - The company noted a generational shift in ophthalmology, with a growing emphasis on work-life balance among physicians, impacting practice productivity [8][9] LDD Sales Performance - LDD sales remained strong throughout 2024 and continued into Q1 2025, indicating a robust demand for capital equipment [11][12] - LALs offer significantly better outcomes for patients compared to monofocal lenses, which incentivizes practices to adopt them despite economic pressures [12][13] Future Expectations - The company anticipates a **20% growth in LAL sales** for Q2 2025, with expectations of a stronger second half of the year as economic conditions stabilize [17][19] - Guidance for 2025 is wide-ranging, reflecting uncertainty in consumer behavior and macroeconomic conditions [20][21] International Market Opportunities - Recent approvals in international markets (e.g., Korea, EU) are expected to contribute modestly to sales, with a focus on building clinical data and key opinion leaders in these regions [28][44][49] Education and Support Initiatives - RxSight plans to enhance education and marketing support for practices to optimize the implementation of their technology, driven by feedback from customers [30][32] - The company aims to address utilization challenges and improve patient outcomes through systematic dissemination of information [32][34] Utilization Trends - There has been a slowdown in the growth of LDD procedures, attributed to macroeconomic factors affecting patient confidence [36][38] - The installed base of LDDs is growing, but the ramp-up in utilization has not met expectations compared to previous years [36][40] Physician Demographics - The adoption of RxSight's technology spans a range of physician experience levels, with younger doctors more inclined to adopt new technologies for career advancement [41][42] Conclusion - RxSight is navigating a challenging macroeconomic environment while maintaining strong sales in LDDs and LALs. The company is focused on education, international expansion, and adapting to market dynamics to drive future growth [44][49]

Core Insights - RxSight, Inc. reported a strong financial performance for Q1 2025, with total revenue reaching $37.9 million, a 28% increase from $29.5 million in Q1 2024, driven by significant growth in Light Adjustable Lens (LAL) sales [4][9] - The company continues to emphasize the clinical value of its Light Adjustable Lens, which is gaining traction among cataract surgeons, and believes that customization and post-operative adjustability will be key trends in premium cataract surgery [3][9] Financial Performance - Total revenue for Q1 2025 was $37.9 million, up 28% from $29.5 million in Q1 2024, with LAL revenue increasing by 37% and Light Delivery Device (LDD) revenue rising by 8% [4][9] - Gross profit for Q1 2025 was $28.3 million, representing 74.8% of revenue, an increase from $20.7 million or 70.1% of revenue in Q1 2024, attributed to lower cost of sales and a favorable product mix [5][9] - Operating expenses for Q1 2025 totaled $39.0 million, a 24% increase from $31.4 million in Q1 2024, reflecting investments in LDD and R&D [6][9] - The net loss for Q1 2025 was $(8.2) million, or $(0.20) per share, an improvement from a net loss of $(9.1) million, or $(0.25) per share in Q1 2024 [7][9] Guidance and Market Position - The company reiterated its full-year 2025 revenue guidance of $160.0 million to $175.0 million, indicating growth of 14% to 25% compared to 2024 [10] - Gross margin is expected to be in the range of 71% to 73%, while operating expenses are projected to be between $150.0 million and $160.0 million, reflecting a 10% to 18% increase compared to 2024 [10][11] - RxSight sold 27,579 LALs in Q1 2025, a 36% increase in procedure volume compared to the same period in 2024, and expanded its installed base of LDDs to 1,044, a 43% increase year-over-year [9][10]

最近网上火的东西越来越抽象了。 比如这美国山海经是啥？脑腐生物又是啥？ 让我们走近科技，保持人类理性，陷入AI疯狂。 最近我的抖音变得好难看，挤满了打着美国山海经和脑腐生物Tag的产物。 如果不知道这俩是什么，那你也很有可能已经刷到过下面这种类似视频。 专业一点，它们的学名叫做意大利脑腐生物（Italian Brainrot Animals），指用人工智能生成的荒诞图像。图内生物结合了超现实主义风格的创作。元素包括 动物、日常物品、食物、武器和想象成分，佐以意大利味儿的名字和配音生成视频（原因可能是意大利口音在TikTok上老被嘲讽）。 圈内TOP梯队的之一——Tung Tung Tung Sahur可以说是里面最火的了。第一条关于它的视频已经在Tiktok上斩获了超740万的流量，点赞也已经过了500万。 在Youtube上，关于这个东西的视频也正在泛滥成灾。 还有人二创出了Tung Tung Tung Sahur的约会、用木棍打别人屁股、和耐克鲨鱼1v1、斗殴被警察带走等一系列视频。这家伙的生活简直比我的还要丰富不 少。 图源：左@怪物彼岸花，右@五十岚上夏 估计各位的第一反应都跟我一样：这啥啊..... ...

Company Overview - RxSight, Inc. is an ophthalmic medical device company focused on providing high-quality customized vision for patients after cataract surgery [3] - The company offers the RxSight Light Adjustable Lens system, which includes the RxSight Light Adjustable Lens (LAL/LAL+), Light Delivery Device (LDD™), and accessories, representing the first and only commercially available intraocular lens technology that can be adjusted post-surgery [3] Upcoming Events - RxSight's management is scheduled to present at the Bank of America Healthcare Conference in Las Vegas on May 14, 2025, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time [2] - A live and archived webcast of the presentation will be accessible for interested parties [2] Contact Information - Shelley B. Thunen serves as the Chief Financial Officer and can be contacted via email at sthunen@rxsight.com [4] - Oliver Moravcevic is the VP of Investor Relations and can be reached at omoravcevic@rxsight.com [4]